People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CHF Solutions, Inc. | — | Biotechnology | Series A | $33.0M | $17.0M | 2010 |
| NEUROONE MEDICAL TECHNOLOGIES Corp | — | Biotechnology | Series A | $21.2M | $1.4M | 2017 |
| BioRestorative Therapies, Inc. | — | Biotechnology | Series A | $19.8M | $4.0M | 2025 |
| Biotricity Inc. | — | Biotechnology | Series A | $10.6M | $6.0M | 2016 |
| NeuroOne, Inc. | — | Biotechnology | Seed | $1.5M | $67.7M | 2016 |
David A. Rosa at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David A. Rosa on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Buckman | 2 | 10 |
| David Rosa | 2 | 5 |
| JEFFREY S. MATHIESEN | 2 | 4 |
| Paul A Buckman | 2 | 3 |
| Thomas A. Bachinski | 2 | 2 |
| Ronald A. McClurg | 2 | 2 |
| Mark A. Christianson | 2 | 2 |
| Suraj A. Kalia | 2 | 2 |
| Steve Salmon | 1 | 6 |
| John L. Erb | 1 | 5 |
| Jon Salveson | 1 | 5 |
| Gregory D. Waller | 1 | 4 |
| William Peters | 1 | 3 |
| Norman Betts | 1 | 3 |
| Charles S. Ryan | 1 | 3 |
| John Erb | 1 | 3 |
| Mark Harvey | 1 | 3 |
| Patricia Kennedy | 1 | 3 |
| Warren Watson | 1 | 3 |
| Donal O'Dwyer | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.